Physician profile
Lori S Beisel
NPI 1235683665
$1,989.74
in general payments reported to CMS, 2019-2025
20 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $184 · 2023: $654 · 2024: $693 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743 · Education: $61.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.34 |
| Education | $61.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $373.13 | 2024-2025 | Airsupra, Farxiga |
| Abbvie INC. | $348.49 | 2022-2025 | |
| Astellas Pharma US INC | $216.14 | 2023-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $203.26 | 2022-2024 | Xarelto |
| Lilly USA, LLC | $200.01 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $160.23 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.78 | 2023-2024 | Jardiance |
| Pfizer INC. | $68.00 | 2023-2024 | |
| Glaxosmithkline, LLC. | $51.38 | 2023 | Shingrix, Arexvy, Boostrix |
| Amgen INC. | $50.04 | 2023-2024 | Prolia, Evenity |
| Ironwood Pharmaceuticals, INC | $44.15 | 2023 | Linzess |
| Boston Scientific Corporation | $33.84 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $33.43 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $21.92 | 2022 | |
| Abbott Laboratories | $18.65 | 2024 | Freestyle Libre 3 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $17.28 | 2025 | The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $17.24 | 2024 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $17.21 | 2023 | |
| Medtronic, INC. | $15.62 | 2025 | Intellis Adaptivestim |
| Shield Therapeutics INC | $13.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Beisel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.